La plateforme SIMCaT se dote de l’Hyperion XTi
Le SIRIC Montpellier Cancer et l’IRCM sont heureux d’annoncer l’arrivée de l’Hyperion XTi
Le SIRIC Montpellier Cancer et l’IRCM sont heureux d’annoncer l’arrivée de l’Hyperion XTi
Priority Session – Latest advances in imaging andtargeted radionuclide therapy Priority Session – Prof. Kevin Prise (Queen’s University Belfast, Ireland): New strategies for targeted alpha therapies in prostate cancer Priority Session – Dr. Timothée David (IRCM, France): In situ vaccine induced by intermediate dose of targeted radionuclide therapy Panacea Session – Cachexia and Cancer Panacea